Comparative Benchmarking
In the context of the broader market, ZNTL competes directly with industry leaders such as RNAC and CGEN. With a market capitalization of $154.75M, it holds a significant position in the sector. When comparing efficiency, ZNTL's gross margin of N/A stands against RNAC's 100.00% and CGEN's 12.74%. Such benchmarking helps identify whether Zentalis Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
